Who founded Belhaven Biopharma?

Belhaven Biopharma was founded by Scott Lyman, Dave Neal in 2020.

How much funding has Belhaven Biopharma raised?

Belhaven Biopharma has disclosed $32.3M raised across 1 of its 3 known rounds.

Where is Belhaven Biopharma headquartered?

Belhaven Biopharma is headquartered in Chapel Hill, US.

Belhaven Biopharma

Chapel Hill, US · Founded 2020 · Delaware corporation

Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.

Biotech Healthtech Medical Devices

Founders & leadership

Belhaven Biopharma was founded in 2020 by Scott Lyman and Dave Neal.

Scott LymaninCEO and Co-Founder, Chairman of the Board

Dave NealinCFO and Co-Founder, Board Member

Board

Wes WheelerBoard director

Derek WinstanlyBoard director

Funding

SEC filings, press & company announcements

$32.3M disclosed across 1 of 3 rounds · 2025

Undisclosed amountSeed RoundJan 2025
Source ↗

▶$32.3MraisedOct 2025 · 222 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Wes WheelerDirector
David Algon NealExecutive Officer, Director
Derek WinstanlyDirector
Scott David LymanExecutive Officer, Director

Offering amount: $32.3M
Amount sold: $32.3M
First sale: Aug 2025
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Biohaven16 shared keywordsBiohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.

Companies competing with Belhaven Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Belhaven Biopharma Inc. has filed a notice of an exempt offering of securities to raise $32,289,627.00 in New Funding. - intelligence360intelligence360.news · Oct 2025

Belhaven Biopharma raises $11M for needle-free allergy treatment - Triangle Business Journalbizjournals.com · Oct 2025

Belhaven Biopharma Initiates a Pivotal Biocomparability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Nasdepi(R) vs. Epinephrine Intramuscular Injections | Newswirenewswire.com · Oct 2025

Belhaven Biopharma Closes Oversubscribed Series a to Fund the Development of Nasdepi(R) Program Moves Into Late Stage Clinical and Manufacturing Through NDA Approvalfinance.yahoo.com · Aug 2025

Belhaven Biopharma Secures $11 Million in Funding for Nasdepi Clinical Program and FDA Preparation - PharmaSourcepharmasource.global · Jan 2025

Belhaven Biopharma Raises $11M to Advance Nasdepi(R): The Dry Powder Nasal Breakthrough for Anaphylaxis - BioSpacebiospace.com · Jan 2025

Frequently asked questions

What does Belhaven Biopharma do?: Belhaven Bio develops a temperature-stable, needle-free delivery device for epinephrine and other emergency medications, designed to be more compact, affordable, and longer-lasting than traditional liquid injectables for patients with severe allergies and anaphylaxis conditions.
Who founded Belhaven Biopharma?: Belhaven Biopharma was founded by Scott Lyman, Dave Neal in 2020.
How much funding has Belhaven Biopharma raised?: Belhaven Biopharma has disclosed $32.3M raised across 1 of its 3 known rounds.
Where is Belhaven Biopharma headquartered?: Belhaven Biopharma is headquartered in Chapel Hill, US.